Entrada Therapeutics, Inc.
Clinical trials sponsored by Entrada Therapeutics, Inc., explained in plain language.
Biotech developing intracellular biologics for rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New hope for duchenne: experimental drug targets genetic flaw
Disease control Recruiting nowThis study tests an investigational drug called ENTR-601-44 in 24 boys and young men with Duchenne muscular dystrophy (DMD) whose genetic mutation can be treated by skipping a specific part of the gene (exon 44). The trial has two parts: first, to find the safest and most effecti…
Phase 1/2 • Sponsor: Entrada Therapeutics, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for duchenne: experimental drug ENTR-601-45 enters human trials
Disease control Recruiting nowThis study tests an investigational drug called ENTR-601-45 in people with Duchenne muscular dystrophy (DMD) who have a specific genetic change (exon 45 skipping). The goal is to check the drug's safety, find the right dose, and see if it can help muscles work better. About 24 ma…
Phase 1/2 • Sponsor: Entrada Therapeutics, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC